- Home
- AVTX vs PLX Comparison
AVTX vs PLX Comparison
Compare AVTX & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- PLX
- Stock Information
- Founded
- AVTX 2011
- PLX 1993
- Country
- AVTX United States
- PLX United States
- Employees
- AVTX N/A
- PLX N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AVTX Health Care
- PLX Health Care
- Exchange
- AVTX Nasdaq
- PLX Nasdaq
- Market Cap
- AVTX 248.3M
- PLX 204.9M
- IPO Year
- AVTX 2015
- PLX 1998
- Fundamental
- Price
- AVTX $18.62
- PLX $1.86
- Analyst Decision
- AVTX Strong Buy
- PLX Strong Buy
- Analyst Count
- AVTX 9
- PLX 1
- Target Price
- AVTX $30.14
- PLX $12.00
- AVG Volume (30 Days)
- AVTX 351.6K
- PLX 553.8K
- Earning Date
- AVTX 11-06-2025
- PLX 11-13-2025
- Dividend Yield
- AVTX N/A
- PLX N/A
- EPS Growth
- AVTX N/A
- PLX N/A
- EPS
- AVTX N/A
- PLX 0.07
- Revenue
- AVTX $192,000.00
- PLX $61,840,000.00
- Revenue This Year
- AVTX N/A
- PLX $14.53
- Revenue Next Year
- AVTX N/A
- PLX $75.77
- P/E Ratio
- AVTX N/A
- PLX $26.49
- Revenue Growth
- AVTX N/A
- PLX 35.41
- 52 Week Low
- AVTX $3.39
- PLX $1.32
- 52 Week High
- AVTX $19.41
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- AVTX 64.08
- PLX 37.55
- Support Level
- AVTX $16.75
- PLX $1.71
- Resistance Level
- AVTX $19.29
- PLX $1.83
- Average True Range (ATR)
- AVTX 1.41
- PLX 0.13
- MACD
- AVTX 0.17
- PLX -0.03
- Stochastic Oscillator
- AVTX 87.31
- PLX 23.08
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.